title: Baseline apnoea/hypopnoea index and high-sensitivity C-reactive protein for the risk of recurrence of atrial fibrillation after successful electrical cardioversion: a predictive model based upon the multiple effects of significant variables.
abstract: OBJECTIVE
  We tested apnoea/hypopnoea index (AHI), high-sensitivity (hs) C-reactive protein and clinical/instrumental variables as predictors of atrial fibrillation (AF) recurrence over 1-year follow-up after successful electrical cardioversion.
  
  
  RESULTS
  We enrolled 158 consecutive patients. Apnoea/hypopnoea index was assessed with standard overnight polysomnography and hs-C-reactive protein with immunonephelometry assay the day before electrical cardioversion. Atrial fibrillation recurrences occurred in 81 patients (51%). Predictors at univariate analysis were: AHI > or = 15 events/h (P = 0.001), hs-C-reactive protein >0.30 mg/dL (P = 0.009), AF duration >3 days (P = 0.008), diabetes (P = 0.03), and ongoing anti-arrhythmic therapy at the time of electrical cardioversion (P = 0.03). Survival analysis confirmed that patients with AHI > or = 15 events/h and hs-C-reactive protein > 0.30 mg/dL had a higher recurrence rate of AF (log rank P = 0.0006 and P = 0.01, respectively). Predictors at multivariate analysis were: AHI > or = 15 events/h (P = 0.003), hs-C-reactive protein > 0.30 mg/dL (P = 0.01) and ongoing anti-arrhythmic therapy (P = 0.04). A predictive model based upon the multiple effects of significant variables plus age as a continuous variable stratified the risk of AF recurrence, more than tripled with all dichotomized variables altered with respect to normal variables (85 vs. 27%).
  
  
  CONCLUSIONS
  AHI > or = 15 events/h and hs-C-reactive protein > 0.30 mg/dL are the strongest predictors of the predictors chosen of AF recurrence after successful electrical cardioversion over 1-year follow-up.
authors.affiliation: Cardiology Division, Santa Maria della Stella Hospital, Orvieto, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Mazza
authors.forename: Maria G
authors.initials: MG
authors.lastname: Bendini
authors.forename: Marco
authors.initials: M
authors.lastname: Cristofori
authors.forename: Stefano
authors.initials: S
authors.lastname: Nardi
authors.forename: Massimo
authors.initials: M
authors.lastname: Leggio
authors.forename: Raffaele
authors.initials: R
authors.lastname: De Cristofaro
authors.forename: Andrea
authors.initials: A
authors.lastname: Giordano
authors.forename: Laura
authors.initials: L
authors.lastname: Cozzari
authors.forename: Giampiero
authors.initials: G
authors.lastname: Giordano
authors.forename: Riccardo
authors.initials: R
authors.lastname: Cappato
mesh_terms: D000328:Adult; D000368:Aged; D001281:Atrial Fibrillation / Q000097:blood / Q000175:diagnosis* / Q000517:prevention & control*; D002097:C-Reactive Protein / Q000032:analysis*; D002304:Cardiac Pacing, Artificial / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D017063:Outcome Assessment, Health Care / Q000379:methods*; D016016:Proportional Hazards Models; D012008:Recurrence; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D012680:Sensitivity and Specificity; D020181:Sleep Apnea, Obstructive / Q000175:diagnosis*; D016896:Treatment Outcome
chemical_list: D002097:C-Reactive Protein